Use of buprenorphine in pregnancy: Patient management and effects on the neonate

Rolley E. Johnson, Hendrée E. Jones, Gabriele Fischer

Research output: Contribution to journalArticle

Abstract

It is estimated that 55-94% of infants born to opioid-dependent mothers in US will show signs of opioid withdrawal. Buprenorphine has been reported to produce little or no autonomic signs or symptoms of opioid withdrawal following abrupt termination in adults. To date, there have been 21 published reports representing approximately 15 evaluable cohorts of infants exposed to buprenorphine in utero. Of approximately 309 infants exposed, a neonatal abstinence syndrome (NAS) has been reported in 62% infants with 48% requiring treatment; apparently greater than 40% of these cases are confounded by illicit drug use. The NAS associated with buprenorphine generally appears within 12-48 h, peaks at approximately 72-96 h, and lasts for 120-168 h. These results appear similar to or less than that observed following in utero exposure to methadone. From a review of the literature, buprenorphine appears to be safe and effective in both mother and infant with an NAS that may differ from methadone both qualitatively and quantitatively.

Original languageEnglish (US)
JournalDrug and Alcohol Dependence
Volume70
Issue number2 SUPPL.
DOIs
StatePublished - May 21 2003

Fingerprint

Buprenorphine
Neonatal Abstinence Syndrome
pregnancy
infant
Newborn Infant
Opioid Analgesics
Pregnancy
Methadone
management
withdrawal
Mothers
Street Drugs
Signs and Symptoms
drug use

Keywords

  • Buprenorphine
  • Neonatal abstinence syndrome
  • Opioid dependence
  • Perinatal addiction
  • Pregnancy
  • Treatment

ASJC Scopus subject areas

  • Medicine(all)
  • Behavioral Neuroscience
  • Toxicology
  • Health(social science)

Cite this

Use of buprenorphine in pregnancy : Patient management and effects on the neonate. / Johnson, Rolley E.; Jones, Hendrée E.; Fischer, Gabriele.

In: Drug and Alcohol Dependence, Vol. 70, No. 2 SUPPL., 21.05.2003.

Research output: Contribution to journalArticle

Johnson, Rolley E. ; Jones, Hendrée E. ; Fischer, Gabriele. / Use of buprenorphine in pregnancy : Patient management and effects on the neonate. In: Drug and Alcohol Dependence. 2003 ; Vol. 70, No. 2 SUPPL.
@article{523763c35f244ee89af1b8d051951dc5,
title = "Use of buprenorphine in pregnancy: Patient management and effects on the neonate",
abstract = "It is estimated that 55-94{\%} of infants born to opioid-dependent mothers in US will show signs of opioid withdrawal. Buprenorphine has been reported to produce little or no autonomic signs or symptoms of opioid withdrawal following abrupt termination in adults. To date, there have been 21 published reports representing approximately 15 evaluable cohorts of infants exposed to buprenorphine in utero. Of approximately 309 infants exposed, a neonatal abstinence syndrome (NAS) has been reported in 62{\%} infants with 48{\%} requiring treatment; apparently greater than 40{\%} of these cases are confounded by illicit drug use. The NAS associated with buprenorphine generally appears within 12-48 h, peaks at approximately 72-96 h, and lasts for 120-168 h. These results appear similar to or less than that observed following in utero exposure to methadone. From a review of the literature, buprenorphine appears to be safe and effective in both mother and infant with an NAS that may differ from methadone both qualitatively and quantitatively.",
keywords = "Buprenorphine, Neonatal abstinence syndrome, Opioid dependence, Perinatal addiction, Pregnancy, Treatment",
author = "Johnson, {Rolley E.} and Jones, {Hendr{\'e}e E.} and Gabriele Fischer",
year = "2003",
month = "5",
day = "21",
doi = "10.1016/S0376-8716(03)00062-0",
language = "English (US)",
volume = "70",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",
number = "2 SUPPL.",

}

TY - JOUR

T1 - Use of buprenorphine in pregnancy

T2 - Patient management and effects on the neonate

AU - Johnson, Rolley E.

AU - Jones, Hendrée E.

AU - Fischer, Gabriele

PY - 2003/5/21

Y1 - 2003/5/21

N2 - It is estimated that 55-94% of infants born to opioid-dependent mothers in US will show signs of opioid withdrawal. Buprenorphine has been reported to produce little or no autonomic signs or symptoms of opioid withdrawal following abrupt termination in adults. To date, there have been 21 published reports representing approximately 15 evaluable cohorts of infants exposed to buprenorphine in utero. Of approximately 309 infants exposed, a neonatal abstinence syndrome (NAS) has been reported in 62% infants with 48% requiring treatment; apparently greater than 40% of these cases are confounded by illicit drug use. The NAS associated with buprenorphine generally appears within 12-48 h, peaks at approximately 72-96 h, and lasts for 120-168 h. These results appear similar to or less than that observed following in utero exposure to methadone. From a review of the literature, buprenorphine appears to be safe and effective in both mother and infant with an NAS that may differ from methadone both qualitatively and quantitatively.

AB - It is estimated that 55-94% of infants born to opioid-dependent mothers in US will show signs of opioid withdrawal. Buprenorphine has been reported to produce little or no autonomic signs or symptoms of opioid withdrawal following abrupt termination in adults. To date, there have been 21 published reports representing approximately 15 evaluable cohorts of infants exposed to buprenorphine in utero. Of approximately 309 infants exposed, a neonatal abstinence syndrome (NAS) has been reported in 62% infants with 48% requiring treatment; apparently greater than 40% of these cases are confounded by illicit drug use. The NAS associated with buprenorphine generally appears within 12-48 h, peaks at approximately 72-96 h, and lasts for 120-168 h. These results appear similar to or less than that observed following in utero exposure to methadone. From a review of the literature, buprenorphine appears to be safe and effective in both mother and infant with an NAS that may differ from methadone both qualitatively and quantitatively.

KW - Buprenorphine

KW - Neonatal abstinence syndrome

KW - Opioid dependence

KW - Perinatal addiction

KW - Pregnancy

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0038664367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038664367&partnerID=8YFLogxK

U2 - 10.1016/S0376-8716(03)00062-0

DO - 10.1016/S0376-8716(03)00062-0

M3 - Article

C2 - 12738353

AN - SCOPUS:0038664367

VL - 70

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

IS - 2 SUPPL.

ER -